Abstract 14770: Reduction With Evolocumab in Complex Coronary Disease Requiring Revascularization: Insights From the FOURIER Trial

医学 传统PCI Evolocumab公司 血运重建 心脏病学 内科学 经皮冠状动脉介入治疗 支架 心肌梗塞 外科 载脂蛋白B 胆固醇 载脂蛋白A1
作者
Kazuma Oyama,Remo H M Furtado,Antônio Fagundes,Thomas A. Zelniker,Minao Tang,Julia Kuder,Sabina A. Murphy,Andrew Hamer,Huei Wang,Anthony Keech,Terje R. Pedersen,Robert P. Giugliano,Marc S. Sabatine,Brian Bergmark
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:3
标识
DOI:10.1161/circ.142.suppl_3.14770
摘要

Introduction: Although PCSK9 inhibitors induce plaque regression and reduce the risk of coronary revascularization overall, their ability to specifically reduce the risk of complex coronary atherosclerosis requiring revascularization has not been explored. Methods: FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with ASCVD on statin therapy (median achieved LDL-C 32 mg/dL vs. 89 mg/dL) followed for a median of 2.2 years. The study database was blindly reviewed to assess characteristics of coronary revascularization procedures. Complex revascularization was the composite of complex PCI (per GLOBAL LEADERS criteria, at least one of: multivessel PCI, 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI with 2 or more stents, or total stent length >60 mm) or CABG. PCI complications included no-reflow, side branch loss, thrombus formation, major dissection, or perforation. The effects of evolocumab on types of revascularization and PCI complications were evaluated using Cox proportional hazards models. Results: 1724 patients underwent revascularization procedures during follow-up. Evolocumab reduced the risk of non-complex PCI by 22% (HR 0.78; 95%CI 0.70-0.88; P<0.001) and the risk of complex revascularization by 29% (HR 0.71; 95%CI 0.61-0.84; P<0.001), including complex PCI by 33% (HR 0.67; 95%CI 0.54-0.84; P<0.001) and CABG by 24% (HR 0.76; 95%CI 0.60-0.96; P=0.019; Figure). The incidence of reported PCI complications tended to be lower with evolocumab (HR 0.74; 95% CI 0.49-1.11). Conclusions: Adding evolocumab to statin therapy reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually. Together with prior coronary imaging findings, these data suggest very aggressive LDL-C lowering to <1 mmol/L has beneficial effects on coronary atherosclerosis burden, anatomical complexity, and the need for intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
醉熏的灵发布了新的文献求助10
刚刚
刚刚
Ahan发布了新的文献求助10
1秒前
小石头完成签到,获得积分10
2秒前
SciGPT应助碧蓝青梦采纳,获得10
2秒前
科研通AI6.4应助天天向上采纳,获得10
3秒前
3秒前
ZBQ完成签到,获得积分10
4秒前
要减肥的以一完成签到 ,获得积分10
4秒前
小鳄鱼一只完成签到,获得积分10
4秒前
兆吉发布了新的文献求助10
4秒前
victormanboy3发布了新的文献求助10
5秒前
6秒前
顾九完成签到 ,获得积分10
6秒前
7秒前
顺心的翠丝完成签到 ,获得积分10
8秒前
乐观的蜜蜂完成签到,获得积分10
8秒前
9秒前
桐桐应助出其东门采纳,获得10
10秒前
10秒前
小二郎应助ldh采纳,获得10
10秒前
10秒前
12秒前
qqq发布了新的文献求助10
12秒前
12秒前
12秒前
14秒前
StudentYu发布了新的文献求助10
14秒前
Hayat发布了新的文献求助30
14秒前
研友_LmAvmL发布了新的文献求助10
16秒前
16秒前
张欢馨应助车干采纳,获得10
18秒前
天天向上发布了新的文献求助10
18秒前
senli2018发布了新的文献求助10
18秒前
科研通AI6.4应助senli2018采纳,获得10
18秒前
兆吉完成签到,获得积分10
18秒前
吴晨曦发布了新的文献求助10
19秒前
张欢馨应助碳化硅膜采纳,获得10
19秒前
20秒前
英姑应助研友_LmAvmL采纳,获得10
20秒前
高分求助中
Markov Chain Monte Carlo 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Common Foundations of American and East Asian Modernisation: From Alexander Hamilton to Junichero Koizumi 5000
Pediatric Dermoscopy Trichoscopy & Onychoscopy 2030
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
Handbuch Trainingswissenschaft – Trainingslehre 500
Additive Manufacturing Design and Applications (ASM Handbook, Volume 24A) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7576585
求助须知:如何正确求助?哪些是违规求助? 9156198
关于积分的说明 19587954
捐赠科研通 7160479
什么是DOI,文献DOI怎么找? 3265053
关于科研通互助平台的介绍 2430187
邀请新用户注册赠送积分活动 2255662